A Randomized Clinical Trial on the Efficacy and Cost-efficacy of Adding on a Mindfulness-based Therapy to Standard Medical Prophylaxis in the Treatment of Patients With Chronic Migraine Associated to Medication Overuse Following Structured Withdrawal: the Mind-CM Study
The Mind-CM study, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, aims to evaluate the efficacy and cost-effectiveness of integrating mindfulness-based therapy with standard pharmacological prophylaxis in chronic migraine patients. Given the prevalence of chronic migraine and the significant burden of medication overuse, successful outcomes could position mindfulness therapy as a viable adjunct treatment, potentially leading to reduced healthcare costs and improved patient quality of life. The market for migraine treatments is substantial, with ongoing demand for innovative, effective solutions. If the study demonstrates significant benefits, it may attract interest from pharmaceutical companies looking to expand their product offerings in the migraine space, as well as healthcare providers seeking cost-effective treatment options.
Indication: Chronic Migraine
Modality: behavioral intervention
Target: Mindfulness-based therapy as an adjunct to pharmacological prophylaxis for chronic migraine management.
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Mindfulness-based therapy as an adjunct to pharmacological prophylaxis for chronic migraine management.
View original source fields
Condition raw: Chronic Migraine, Medication Overuse Headache
Condition normalized: Chronic Migraine, Medication Overuse Headache
Modality raw: behavioral intervention
Modality normalized: behavioral intervention
Target raw: Mindfulness-based therapy as an adjunct to pharmacological prophylaxis for chronic migraine management.
Target normalized: Mindfulness-based therapy as an adjunct to pharmacological prophylaxis for chronic migraine management.